Kalaris Therapeutics (KLRS) investor relations material

Executive summary

• Report covers the quarter ended June 30, 2025, following a reverse recapitalization merger with AlloVir, Inc., with Legacy Kalaris as the accounting acquirer.

• Focus remains on developing TH103, a novel anti-VEGF drug for retinal diseases, with Phase 1 clinical trial enrollment ongoing and initial data expected in Q4 2025.

• No revenue generated; operations funded by equity, convertible notes, and merger proceeds.

• Expanded leadership team with the addition of a Senior VP of Clinical with extensive ophthalmology experience.

Financial highlights

• Net loss for Q2 2025 was $11.4 million ($0.61 per share), compared to $5.7 million ($4.26 per share) in Q2 2024; six-month net loss was $21.5 million, up from $9.1 million year-over-year.

• Cash and cash equivalents at June 30, 2025, were $88.4 million, up from $1.6 million at December 31, 2024, primarily due to the merger.

• Operating expenses for Q2 2025 were $12.3 million, up from $4.2 million in Q2 2024, driven by increased R&D and G&A costs.

• Research and development expenses rose to $8.4 million in Q2 2025, mainly due to clinical trial initiation and manufacturing scale-up.

• General and administrative expenses increased to $3.8 million in Q2 2025, mainly due to higher legal, professional, and personnel costs post-merger.

Outlook and guidance

• Cash runway expected into Q4 2026 based on current operating plans; additional capital will be needed for future development and commercialization.

• Initial clinical data from the Phase 1 TH103 trial anticipated in Q4 2025.

• Expenses expected to increase as clinical development progresses and corporate infrastructure expands.